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ABSTRACT
We examined the role of post-transcriptional
mechanisms in controlling utrophin A mRNA
expression in slow versus fast skeletal muscles.
First, we determined that the half-life of utrophin A
mRNA is significantly shorter in the presence of
proteins isolated from fast muscles. Direct plasmid
injection experiments using reporter constructs
containing the full-length or truncated variants of
the utrophin 3’UTR into slow soleus and fast
extensor digitorum longus muscles revealed that a
region of 265 nucleotides is sufficient to confer
lower levels of reporter mRNA in fast muscles.
Further analysis of this region uncovered a con-
served AU-rich element (ARE) that suppresses
expression of reporter mRNAs in cultured muscle
cells. Moreover, stability of reporter mRNAs fused to
the utrophin full-length 3’UTR was lower in the
presence of fast muscle protein extracts. This
destabilization effect seen in vivo was lost upon
deletion of the conserved ARE. Finally, we observed
that calcineurin signaling affects utrophin A mRNA
stability through the conserved ARE. These results
indicate that ARE-mediated mRNA decay is a key
mechanism that regulates expression of utrophin
A mRNA in slow muscle fibers. This is the first
demonstration of ARE-mediated mRNA decay reg-
ulating the expression of a gene associated with the
slow myogenic program.
INTRODUCTION
Ever since its discovery, >15 years ago, there has been a
considerable amount of eﬀort to decipher the molecular
events regulating expression of the cytoskeletal protein
utrophin (1,2). These eﬀorts are fueled in part by the
fact that utrophin accumulates at the neuromuscular
junction where it participates in the full diﬀerentiation of
the postsynaptic apparatus (3–6). In addition, directed
expression of utrophin in extrasynaptic compartments of
muscle ﬁbers is considered as a prospective therapeutic
strategy for the treatment of Duchenne muscular dystro-
phy (2,7).
Previous studies led to the notion that the state of
diﬀerentiation and innervation of muscle ﬁbers can
inﬂuence the expression of utrophin A (8–10), the skeletal
muscle isoform (11), mostly through transcriptional
mechanisms. For example, local transcriptional activation
of the utrophin A promoter accounts for the preferential
accumulation of utrophin A mRNAs within synaptic
regions of mature ﬁbers (8,10,12), via activation of
signaling cascades triggered by agrin and neuregulin
(13–15). Although it is well established that utrophin
A preferentially accumulates in synaptic regions of
muscle, we noted a few years ago that slow-twitch,
high oxidative, ﬁbers express more utrophin A in their
extrasynaptic compartments as compared with fast ﬁbers
(16). Subsequently, we demonstrated the involvement of
signaling pathways that promote expression in muscle
of the slower oxidative phenotype, in regulating expres-
sion of utrophin A (17–20). Speciﬁcally, we showed that
calcineurin, a Ca
+2/calmodulin-regulated phosphatase
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In recent years, it has become apparent that in addition
to transcription, post-transcriptional mechanisms can
inﬂuence expression of several mRNAs in all cell types
including skeletal muscle (24). For instance, mRNAs
encoding MyoD, myogenin, acetylcholinesterase (AChE)
and a-dystrobrevin 1 are regulated at multiple post-
transcriptional levels involving mRNA stability, targeting
and translation (25–29). Recently, the contribution of
post-transcriptional mechanisms has also been shown to
play an important role in the regulation of utrophin A in
muscle cells (16,30,31). Thus, although our previous
studies highlighted the role of transcription in regulating
the greater abundance of utrophin A in slow ﬁbers
(see above), we hypothesize that post-transcriptional
events are also involved. Here, we speciﬁcally focused
on the role of mRNA stability in regulating the higher
levels of utrophin A mRNA seen in slow muscle.
Furthermore, through a series of complementary experi-
ments we characterized cis-elements within the utrophin
30UTR, and signaling pathways involved in the post-
transcriptional regulation of utrophin A mRNA in slow
versus fast muscles.
MATERIALS AND METHODS
Animal careand protocols
All animal care and experimental procedures were
performed in accordance with the guidelines established
by the Canadian Council of Animal Care. These
procedures were approved by the Institutional Animal
Care and Research Advisory Committee of Laurentian
University, or by the University of Ottawa Animal Care
and Use Committee. For inhibiting calcineurin activity in
skeletal muscle, C57 BL/6 mice were treated twice daily
for 14 days with either cyclosporine A (CsA; 25mg/kg
administered subcutaneously), FK506 (5mg/kg adminis-
tered subcutaneously), or vehicle (control) as previously
described (19). Soleus and extensor digitorum longus
(EDL) muscles from control or treated mice were excised
and frozen in liquid nitrogen. Muscles were subsequently
processed for in vitro stability assays (see below). In
separate experiments, EDL and soleus muscles of C57 Bl/6
mice were directly injected with utrophin 30UTR reporter
constructs (see below) using a procedure described in
detail elsewhere (8,16). These muscles were excised 7 days
later, frozen in liquid nitrogen and subsequently processed
for RT-PCR analysis (see below).
Cell culture
Mouse C2C12 cells (American Type Culture Collection,
Manassas, VA, USA) were plated on 6-well culture dishes
coated with Matrigel (Collaborative Biomedical Products,
Bedford, MA, USA) in Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 20% fetal bovine serum, 292ng/ml L-glutamine and
100 U/ml penicillin–streptomycin in a humidiﬁed chamber
at 378C with 5% CO2. Conﬂuent myoblasts were induced
to diﬀerentiate into myotubes by replacing the growth
medium with diﬀerentiation medium containing 2% horse
serum for 3 days (29).
Invitro stability assays
Proteins were extracted from EDL and soleus muscles
from control mice, and soleus muscles of drug-treated
mice (see above) using 500ml of a homogenization buﬀer
[0.01M Tris pH 8.0, 0.01M KCl, 0.0015M MgCl2, 2.5%
IGEPAL CA-630 (a non-ionic detergent) (Sigma-Aldrich,
Oakville, ON, USA)] containing protease inhibitor
complete mini-tablets as per the manufacturer’s recom-
mendations (Roche Applied Science, Laval, QC, USA).
After homogenization, protein extracts were centrifuged
at 3500g for 10min. Pellets were subsequently vortexed
and incubated at 48C in 100ml extraction buﬀer (0.02M
Tris pH 8.0, 0.45M NaCl, 0.01M EDTA) also containing
protease inhibitor complete mini-tablets. After incubation,
the pelleted fractions were centrifuged at 14000g for
10min and supernatants were collected. This yielded a
protein extract enriched in cytoskeletal and nuclear
fractions that was used for in vitro stability assays. This
fraction was selected because the cytoskeleton has been
previously implicated in regulating utrophin expression
post-transcriptionally (30). The RNA used in these assays
was isolated from C2C12 myotubes using TriPure reagent
(Boehringer Mannheim, Laval, QC, USA). For determi-
nation of LacZ reporter mRNA half-life, RNA was
isolated from C2C12 myotubes that had been transfected
with the appropriate reporter construct (see below).
Degradation assays were performed as described else-
where, with some modiﬁcations (32,33). Brieﬂy, total
RNA from C2C12 cells (0.2mg/ml) and equal amounts of
soleus and EDL protein extracts (0.25mg/ml) were
incubated together in degradation buﬀer (10mM Tris
pH 7.4, 10mM KOAc, 2mM MgOAc, 2mM DTT,
0.1mM Spermine, 1mM ATP, 0.4mM GTP, 10mM
Phosphocreatine, 1mg creatine phosphokinase, 80U
SUPERNasin (Ambion, Austin TX), at 378C. Time 0
was taken as RNA incubated in buﬀer without protein
extracts for 1min at 378C. The reactions were stopped at
diﬀerent time intervals by addition of 200ml of phenol/
chloroform. The RNA was then precipitated with
isopropanol in the presence of yeast tRNA (10mg)
(Sigma-Aldrich) as a carrier. The values of utrophin A,
LacZ and S12 transcripts remaining at each time point
were determined through RT-PCR analysis (see below).
Values were then plotted on a logarithmic scale as a
function of time, and the half-life was calculated using
linear equations (34). Four separate experiments were
conducted, using four diﬀerent muscle extracts. Half-life
values were then determined relative to appropriate
controls in each individual experiment. Relative half-life
values were averaged and compared between samples.
In vitro stability assays were also performed using
labeled RNA probes corresponding to regions of the
utrophin A 30UTR. For these, in vitro transcription
reactions were ﬁrst performed using MAXIscript
(Ambion) and a 299 to 603nt region from the mouse
utrophin 30UTR PCR product containing a T7 RNA
polymerase-binding site. This PCR product was obtained
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TTTTTTTTTTTAGAATGCCTGCCTACTCCACAT-30
and 50-GATTTAATACGACTCACTATAGGGACTC
AGCCATGGGAAAGTG-30. Labeled RNA transcripts
were produced by including [a-
32P] UTP (3000Ci/mmol,
Amersham Biosciences) in the reaction mixtures. The
radioactive probes were puriﬁed using microspin G-50
columns (Amersham Biosciences) and used in stability
assays as described above with protein extracts from
soleus and EDL muscles. Quantitative analyses of the
intensity of the radioactive signals were performed using
a Storm PhosphorImager and the accompanying
ImageQuant Thv2005 software (Molecular Dynamics,
Amersham; Piscataway, NJ, USA).
Plasmid construction
The 30UTR of the mouse full-length ( 2kb) utrophin
mRNA was isolated and subcloned into a LacZ reporter
construct driven by the cytomegalovirus (CMV) promoter
(pCMVsport from Invitrogen) as described previously
(30). Truncated variants of the utrophin 30UTR encom-
passing the ﬁrst 332 and 596 nucleotides were also
generated in a similar manner (30). To generate the
utrophin 30UTR fragment deleted of the conserved 16
nucleotide AU-rich element (ARE), we employed a PCR-
based protocol described elsewhere (29). Brieﬂy, the
utrophin full-length 30UTR cDNA was used as a template,
and two rounds of PCR ampliﬁcation were ﬁrst performed
with the following primers: 50-CATAATGGTAAAACA
GTCAAATAA-30 and the ﬂanking primer 50-TGGTCT
CCTCGAGGCATCTATCCAGCCAG-30 (reaction 1);
and the ﬂanking primer 50-TGGTCTCAAGCTTGGTA
TGTAACAGATTAG-30 and primer 50-ATCAGCCATA
CCAAACGAATAGAT-30 (reaction 2). To remove the
ARE region, we performed a third round of PCR, with the
reaction 1 and reaction 2 PCR products, using the two
ﬂanking primers listed above to yield a product containing
the utrophin 30UTR without the conserved 16nt ARE
region (30UTR ARE). The success of this deletion
approach was conﬁrmed by sequencing.
Transfectionand direct plasmid injection
Plasmid DNA was prepared using the Mega-Prep kit
(Qiagen, Mississauga, ON, USA). DNA pellets were
resuspended in 10mM Tris–HCl, pH 8.5. Transfections
were performed with the Lipofectamine reagent kit
(Invitrogen) according to the manufacturer’s instructions.
Brieﬂy, C2C12 myoblasts at  80% conﬂuency were
transfected with 1mg of utrophin 30UTR-reporter con-
structs together with 1mg of pCIneo (Promega) as a
control, or with a construct containing a constitutively
active variant of calcineurin (pCnA
 ) (17), by using
lipofectamine reagent (Invitrogen). Total RNA was
extracted, and the levels of reporter LacZ mRNA and
neomycin mRNA (to control for transfection eﬃciency)
were determined by RT-PCR analysis (see below).
Transfections examining the eﬀects of deleting the 16nt
ARE from the utrophin 30UTR were done in a similar
fashion. For these, 2mg of pCMVsport plasmid containing
a LacZ gene fused to the SV40 late polyadenylation signal
(SV40 30UTR), the utrophin 30UTR full-length or the
30UTR ARE were transfected. Levels of reporter LacZ
mRNA were standardized to ampicillin mRNA trans-
cribed on the same construct by a separate promoter.
Direct gene transfer was performed using mouse EDL
and soleus muscles as described in detail elsewhere (16).
EDL and soleus muscles were isolated, and injected with
10ml of a solution containing either the utrophin 30UTR
full-length, 30UTR ARE, 30UTR 596 and 30UTR 332
LacZ reporter constructs, together with pCAT control
plasmids used to control for transduction eﬃciency
(concentration of 2–4mg/ml). Injected muscles were excised
and immediately frozen in liquid nitrogen after seven days.
Total RNA was extracted and subsequently analyzed by
RT-PCR (see below). For injection of tibialis anterior
(TA) muscles, 25ml of solution containing either 2mgo f
the utrophin 30UTR full-length or 30UTR ARE reporter
constructs, together with 2mg of pCnA
  or pCIneo
constructs were injected. Muscles were extracted and
processed for RT-PCR analysis after ﬁve days (see below).
RNA extraction and RT-PCR
Total RNA was extracted by using TriPure (Boehringer
Mannheim) as recommended by the manufacturer.
Quantitative RT-PCR was carried out to determine the
relative abundance of: (i) utrophin A and S12 in EDL and
SOL muscles; (ii) utrophin A, S12 and LacZ transcripts
remaining at each time point of the in vitro stability assays;
(iii) LacZ and CAT mRNA levels after direct plasmid
injections; (iv) LacZ and neomycin mRNA levels in
co-transfection experiments of the utrophin 30UTR
reporter constructs with pCIneo or pCnA
  in C2C12
muscle cells; and (v) Lac Z and ampicillin transcripts in
C2C12 muscle cells transfected with utrophin 30UTR full-
length, parental or 30UTR ARE reporter constructs.
These assays were performed using previously described
protocols and primers (16,17,29). Cycle numbers varied
depending on the primers used and they were all within
the linear range of ampliﬁcation (16,29,35). For ampliﬁca-
tion of LacZ, CAT, neomycin and ampicillin mRNAs,
samples were ﬁrst digested using DNase 1 to eliminate
possible plasmid contamination (16,17). In all these
assays, negative controls consisted of reverse transcription
mixtures in which total RNA was replaced with RNase-
free water. PCR products were ﬁrst visualized on 1%
agarose gel containing ethidium bromide.
Labeling intensity of the PCR products, which is
linearly related to the abundance of cDNAs, was
quantiﬁed using Kodak digital science 1D Image analysis
software. For direct plasmid injections, values obtained
for LacZ were standardized relative to the amount of
CAT. For transfection studies in C2C12 muscle cells
involving utrophin 30UTR reporter constructs and pCnA
 ,
values obtained for LacZ were standardized relative to the
amount of neomycin. For transfection studies in C2C12
muscle cells involving the utrophin 30UTR full-length,
SV40 30UTR and 30UTR ARE reporter-constructs,
values obtained for LacZ were standardized to the
amount of ampicillin (29).
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Analysis of variance (ANOVA) and F-tests, or two-tailed
Student’s t-tests were used to analyze the data.
Means SEM are presented throughout. All statistics
were done using Microsoft Excel Analysis ToolPak.
RESULTS
Levels of utrophinA mRNAare greater inslow versus fast
muscles due also to enhanced stability
In an initial series of experiments, we examined the levels
of utrophin A mRNA in fast and slow muscles. As shown
in Figure 1A, levels of utrophin A mRNA in slow soleus
muscles were much higher in comparison with fast EDL
muscles. Quantitative analysis revealed that utrophin A
transcripts were  3-fold higher (P<0.05) in soleus
muscles (Figure 1B). These higher levels of utrophin A
mRNA in slow muscles are in excellent agreement with
previous observations (10,12,16,17).
To determine whether the stability of utrophin A
transcripts is diﬀerent in fast versus slow muscles, we
initially chose to employ a previously described in vitro
stability assay (32,33). The use of an in vitro protocol
under highly controlled and reproducible conditions is
warranted since our preliminary work revealed that
measuring the stability of transcripts in skeletal muscle
of living animals using transcription inhibitors such
as actinomycin D, is unreliable and fraught with
diﬃculties (data not shown). In fact, limitations of this
approach have been discussed previously (34,36) and they
include: (i) the toxicity of the drug which kills the animals
in a few hours making extrapolations of half-life of
relatively stable mRNAs questionable and (ii) the direct
eﬀect of these drugs on the mRNA decay process which
may artiﬁcially alter the rate of degradation of speciﬁc
cellular transcripts.
With the use of this in vitro stability assay, we examined
the degradation of utrophin A mRNA in the presence of
fast(EDL) orslow(soleus)skeletalmuscleproteinextracts.
Total RNA from 3 day-old C2C12 myotubes was
incubated with either fast or slow muscle protein extracts
for diﬀerent time periods in a degradation buﬀer. The
amountofutrophinAmRNAremainingateachtimepoint
was subsequently determined and used to calculate mRNA
decay kinetics (see Materials and Methods section). In the
presence of slow muscle protein extracts, utrophin A
mRNA appeared to degrade at a slower rate in comparison
to mRNA incubated with fast muscle extracts (Figure 2A).
Evaluation of mRNA half-life values revealed that
utrophin A degraded at approximately three times the
rate (P<0.05) in the presence of fast muscle protein
extracts relative to incubation with slow muscle extracts
(Figure 2B). Using qPCR, we also observed a 2 to 3-fold
Figure 2. Utrophin A mRNA decays at a faster rate in the presence of
fast muscle protein extracts. (A) In vitro stability assays were performed
with protein extracts from EDL and soleus (SOL) muscles and RNA
isolated from 3day-old C2C12 myotubes. Examples of vistra green
stained-agarose gels display utrophin A PCR products following 0, 2, 4,
8, 16 and 32min incubation with protein extracts. Note the greater
amount of utrophin A PCR products remaining upon incubation with
the slow SOL muscle protein extracts versus with fast EDL muscle
extracts. (B) Quantitation of the amounts of utrophin A mRNA at each
time point, plotted in a semi-log scale as percentage of RNA seen at
time 0. This analysis revealed that the half-lives seen in the presence of
EDL versus soleus protein extracts were 3.55min and 11.41min,
respectively (n=4 independent experiments).
Figure 1. Levels of utrophin A mRNA are higher in slow versus fast
muscles. (A) Examples of ethidium bromide-stained agarose gels
showing utrophin A and S12 PCR products from EDL and soleus
(SOL) muscles. (B) Quantitation of utrophin A mRNA levels in EDL
muscles expressed as a percentage of those found in SOL muscles and
standardized to S12 transcripts. Note the signiﬁcantly greater amount
of utrophin A mRNA in SOL muscles.
 Indicates a signiﬁcant
diﬀerence from EDL (P<0.05; n=4 independent experiments).
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slow versus fast protein extracts. As a control, we observed
in separate experiments no diﬀerence in the rate of
degradation of S12 transcripts upon incubation with
either fast or slow muscle extracts (P>0.05; <10%
diﬀerence in half-life measurements between fast and
slow protein extracts). These data indicate that in addition
to transcriptional events, increased mRNA stability also
contributes to the diﬀerential abundance of utrophin A
transcripts in slow versus fast muscles.
Acis-element in theutrophin 3’UTR differentially
regulates reporter expression in slow versus fastmuscles
The 30UTRs of host mRNAs can function to regulate the
levels of transcripts present in a cell (37,38). This ability to
control mRNA levels stems from the presence of cis-acting
elements often contained within the 30UTR. Next, we
therefore sought to determine, in vivo, the contribution of
speciﬁc cis-acting elements contained within the mouse
utrophin 30UTR in conferring diﬀerences in mRNA
expression between fast and slow muscles using direct
plasmid injection of reporter constructs in EDL and soleus
muscles of mice (Figure 3A). Direct plasmid injection of a
LacZ reporter construct containing the utrophin full-
length 30UTR led to a  2.5-fold (P<0.05) higher level
of reporter mRNA in soleus versus EDL muscles
(Figure 3B).
Similar to the results obtained with the construct
containing the utrophin full-length 30UTR, direct injection
of a reporter construct with the ﬁrst 596 nucleotides of the
utrophin 30UTR also led to a 2.5-fold (P<0.05) increase
in reporter mRNA expression in soleus versus EDL
muscles (Figure 3B). In contrast, levels of LacZ reporter
mRNAs fused to the ﬁrst 332 nucleotides of the utrophin
30UTR were not signiﬁcantly diﬀerent (P>0.05) between
soleus and EDL muscles (Figure 3B). Interestingly,
relative levels of reporter mRNAs fused to the ﬁrst 332
nucleotides of the utrophin 30UTR in EDL muscles
increased to values comparable to those seen in soleus
muscles. LacZ reporter mRNA levels from soleus muscles
injected with the full length, 1–332 and 1–596 constructs
did not diﬀer signiﬁcantly (P>0.05). Collectively, these
data suggest that nucleotides 332–596 of the utrophin
30UTR contain elements capable of suppressing reporter
mRNA levels in EDL muscles thereby indicating the
Figure 3. A region between nucleotides 332–596 in the utrophin 30UTR decreases reporter mRNA expression in fast muscles. (A) Schematic
representation of reporter constructs containing the full-length utrophin 30UTR, and the ﬁrst 596 and 332 inserted downstream of the LacZ reporter
gene. (B) Mouse EDL and soleus (SOL) muscles were transduced with expression plasmids containing the various lengths of the 30UTR. Note that
LacZ reporter mRNA levels are  60% lower in EDL muscles when fused to either the utrophin full-length 30UTR or the ﬁrst 596 nucleotides.
However, this diﬀerence is lost when LacZ mRNAs are fused to the ﬁrst 332 nucleotides indicating the presence between nucleotides 332 and 596 of
an instability element active in fast EDL muscles.
 Indicates a signiﬁcant diﬀerence from EDL (P<0.05; n=4–5 animals for each construct and in
independent experiments). (C) Example of an in vitro stability assay using a radiolabeled RNA probe corresponding to nucleotide 299–603 of the
utrophin 30UTR incubated for various time periods with protein extracts from EDL and SOL muscles. (D) The intensity of the radioactive signals
seen in these assays was quantiﬁed and plotted on a semi-log scale as a percentage of RNA seen at time 0 (n=4 independent experiments). Note that
the half-lives seen under these conditions were 17.36min and 50.56min when the radiolableld RNA probe was incubated with fast EDL versus slow
SOL protein extracts, respectively.
830 Nucleic Acids Research, 2008, Vol. 36, No. 3presence of a destabilizing element active in vivo, prefer-
entially in fast muscle ﬁbers.
Given these ﬁndings, we sought to illustrate further the
importance of this region in determining the stability of
utrophin A transcripts in fast versus slow muscles. To this
end, we generated a radiolabeled RNA probe correspond-
ing to nucleotides 299–603 of the utrophin 30UTR and
performed in vitro stability assays using protein extracts
from soleus and EDL muscles. As shown in Figure 3C, the
radiolabeled RNA appeared to decay at a faster rate in
the presence of proteins from EDL muscles. Quantitative
analyses of these results showed that indeed, the half-life
of this RNA incubated with fast muscle protein extracts
was approximately three times lower than that seen upon
incubation with extracts from soleus muscles (Figure 3D).
These ﬁndings are important since they further show the
key function of this region within the utrophin 30UTR in
controlling the stability of these transcripts in fast versus
slow muscles.
The 332–596region contains multiple ARE
Sequence analysis of the 332–596 region in the utrophin
30UTR revealed that 72% of the nucleotides are either
adenosine or uridine. Within these 265 nucleotides, we
found three potential ARE known to play key roles in
regulating the turnover of mRNAs (Figure 4A, grey
characters) (39–41). Species comparison revealed that one
of the three AREs is conserved between mouse and human
utrophin 30UTR sequences (Figure 4A, underlined grey
characters).
To determine whether the conserved ARE contributes
to the regulation of utrophin A mRNAs, we generated
full-length utrophin 30UTR LacZ reporter constructs
deleted for this minimal region (ARE; Figure 4B). To
initially examine the eﬀects of deleting the ARE, we ﬁrst
transfected C2C12 muscle cells with reporter constructs
containing either the utrophin full-length 30UTR, the
30UTR ARE or the LacZ gene fused to the SV40 30UTR
(see Materials and Methods section). After 3 days of
diﬀerentiation, transfected cells were harvested and
reporter mRNA levels were examined. RT-PCR analysis
of total mRNA isolated from transfected muscle cells
revealed that the presence of the utrophin full-length
30UTR inhibited reporter mRNA expression as evidenced
by an  80% decrease in LacZ transcript levels (P<0.05)
relative to the levels of reporter mRNA fused to the SV40
Figure 4. The utrophin 30UTR contains a conserved ARE that acts as a destabilizing element. (A) Sequence between nucleotides 332 and 596 of the
utrophin 30UTR. Grey characters denote three potential ARE. The underlined one is an ARE conserved between mouse and human which we
subsequently deleted for further analysis. (B) Schematic representation of the utrophin full-length 30UTR, the full-length version deleted of the
conserved ARE (30UTR ARE) and the SV40 30UTR inserted downstream of the LacZ reporter construct. (C) Analysis of LacZ mRNA levels from
3 day-old C2C12 myotubes transfected with one of the three reporter constructs. Note the decrease in LacZ reporter mRNA expression when fused
to the utrophin full-length 30UTR relative to the SV40 30UTR. Importantly, note also the loss of this eﬀect upon deletion of the conserved ARE.
 Indicates a signiﬁcant diﬀerence relative to SV40 30UTR,
#indicates a signiﬁcant diﬀerence relative to full-length 30UTR [
 (P<0.05);
#(P<0.01)
n=3 independent experiments done in triplicate]. (D) Mouse EDL and soleus (SOL) muscles were injected with plasmids containing the utrophin
30UTR ARE reporter constructs. Note that in contrast to injection with reporter constructs containing the utrophin full-length 30UTR (Figure 3),
expression levels of LacZ mRNA are not diﬀerent between EDL and SOL muscles upon deletion of the conserved ARE (P>0.05); n=5 animals
used in independent experiments.
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fused to the utrophin 30UTR ARE were  4-fold
(P<0.05) higher relative to the levels seen with the
utrophin full-length 30UTR (Figure 4C). Furthermore,
levels of reporter mRNA were not diﬀerent (P>0.05)
between cells transfected with constructs containing the
utrophin 30UTR ARE or the SV40 30UTR (Figure 4C).
Together, these ﬁndings show the presence of an
instability element with the utrophin 30UTR.
Next, we determined if the conserved ARE could also
function in vivo, particularly in a physiological context.
For this, we performed direct plasmid injection of reporter
constructs containing either the full-length 30UTR or
the deleted ARE version into EDL and soleus muscles.
Direct plasmid injection of a reporter construct containing
the utrophin full-length 30UTR resulted in an  2.5-fold
(P<0.05) increase in reporter mRNA expression in soleus
muscles as compared with EDL muscles (Figure 3B). In
contrast, injection of the 30UTR ARE reporter construct
did not lead to a signiﬁcant diﬀerence (P>0.05) in LacZ
mRNA expression between EDL and soleus muscles
(Figure 4D). These observations are consistent with the
idea that the conserved ARE in the utrophin 30UTR acts
as a destabilizing element preferentially active in fast
muscles, as also suggested by experiments presented in
Figure 3.
The utrophinconserved ARE functions asakey regulatory
elementinthepresenceoffastandslowmuscleproteinextracts
Since utrophin A displays diﬀerential mRNA stability in
the presence of either fast or slow muscle protein extracts,
we next established whether the utrophin conserved ARE
could confer diﬀerences in mRNA stability under similar
conditions. Therefore, we performed in vitro stability
assays whereby mRNA collected from C2C12 muscle
cells transfected with LacZ reporter constructs containing
either the utrophin full-length 30UTR or the 30UTR
ARE, were incubated with fast or slow muscle protein
extracts (as described earlier). Consistent with the ability
of the utrophin 30UTR to promote higher levels of
reporter mRNA expression in slow muscles relative to
fast ones (Figure 3), these assays demonstrated greater
reporter mRNA expression over time for the construct
containing the full-length 30UTR in the presence of soleus
protein extracts relative to EDL extracts (Figure 5A).
Quantitative comparisons of the half-life of utrophin full-
length 30UTR reporter mRNAs demonstrated a 50%
(P<0.05) decrease upon incubation with fast versus slow
muscle extracts (Figure 5B).
Deletion of the ARE from the utrophin 30UTR, which
did not signiﬁcantly aﬀect the stability of reporter mRNAs
incubated with slow muscle extracts, had a marked
stabilizing inﬂuence on reporter mRNA expression
incubated with fast muscle protein extracts (Figure 5A).
Indeed, quantitative analyses revealed that deletion of the
ARE from the utrophin 30UTR led to an  2-fold
(P<0.05) increase in reporter mRNA half-life relative to
the half-life seen with mRNAs fused to the utrophin full-
length 30UTR upon incubation with fast EDL muscle
extracts (Figure 5B). Of note, the half-life of reporter
mRNAs containing the utrophin 30UTR ARE incubated
with fast muscle extracts were not signiﬁcantly diﬀerent
(P>0.05) from the half-life seen with constructs contain-
ing the full-length 30UTR incubated with slow muscle
extracts (Figure 5B). It should also be noted that control
experiments showed no diﬀerence in the degradation of
reporter mRNAs fused to the SV40 30UTR upon
incubation with either fast or slow muscle protein extracts
(data not shown). Therefore, the conserved ARE in the
utrophin A 30UTR serves as an instability element in the
presence of fast muscle protein extracts.
Calcineurin regulates the stability of utrophinA mRNA
The phosphatase calcineurin has been shown to have
important roles in maintaining the expression of genes
reﬂective of the slower, high oxidative, myoﬁber program
(21,22). Recently, we showed that stimulation of calci-
neurin signaling promotes expression of utrophin A
mRNA through modest increases in transcription acting
through an NFAT site located within the utrophin A
promoter region (10,17,19). Here, we sought to determine
Figure 5. The conserved ARE in the utrophin 30UTR increases the rate
of decay of reporter mRNAs in fast muscle. (A) Example of ethidium
bromide-stained agarose gels showing LacZ PCR products obtained
following an in vitro stability assay at 0, 30 and 60min of incubation
with EDL or soleus (SOL) protein extracts. Note the greater amount of
LacZ mRNA fused to the utrophin full-length 30UTR that remains
after 30 and 60min incubations with the slow SOL muscle protein
extracts. Also, note the higher levels of LacZ mRNA remaining after 30
and 60min incubations with EDL protein extracts upon deletion of the
conserved ARE in the utrophin 30UTR (compare full-length 30UTR to
30UTR ARE from EDL samples). (B) Quantitation of the relative
half-life expressed as a percentage of the values obtained for LacZ
mRNA fused to the utrophin full-length 30UTR and incubated with
SOL protein extracts. Note the signiﬁcant decrease in the half-life for
LacZ mRNA fused to the utrophin full-length 30UTR upon incubation
with EDL protein extracts relative to SOL. Also, note the signiﬁcant
increase in the half-life of LacZ mRNA upon deletion of the conserved
ARE in the utrophin 30UTR, relative to the utrophin full-length 30UTR
in samples incubated with EDL protein extracts.
 Indicates a signiﬁcant
diﬀerence from SOL;
#indicates a signiﬁcant diﬀerence from other EDL
samples (P<0.05; n=4 independent experiments).
832 Nucleic Acids Research, 2008, Vol. 36, No. 3whether calcineurin signaling also aﬀects utrophin A
mRNA turnover.
To this end, we ﬁrst performed in vitro stability assays.
For these, mRNA from C2C12 myotubes was incubated
with fast or slow muscle protein extracts taken from mice
treated with the speciﬁc calcineurin inhibitor FK506 or
vehicle (as control). FK506 (tacrolimus) acts as a speciﬁc
inhibitor of calcineurin by forming a complex with the
endogenous immunophilin protein FKBP12, thus steri-
cally hindering substrates from accessing the catalytic site
(42–44). As shown in Figure 6A, utrophin A transcripts
decayed at an accelerated rate in the presence of soleus
muscle extracts obtained from FK506-treated mice
relative to vehicle controls. Quantitative assessment of
half-life values revealed an  30% (P<0.05) decrease in
the amount of time required for utrophin A mRNA to
decay to half-maximal values when incubated with soleus
muscle extracts from FK506-treated mice as compared to
vehicle controls (Figure 6B). Similar results were obtained
when in vitro stability assays were conducted with soleus
muscle protein extracts from mice treated with another
calcineurin inhibitor, cyclosporine A (CsA) ( 25%
reduction; P<0.05). Analysis of S12 transcript decay
did not reveal any diﬀerences upon incubation with soleus
muscle protein extracts taken from vehicle- or FK506-
treated mice (Figure 6A).
Due to the negative eﬀects of calcineurin inhibition on
the stability of utrophin A mRNA, we further examined
how altered activity of this enzyme could impact the
ability of the utrophin 30UTR to regulate mRNA
expression. First, we studied the eﬀects of increased
calcineurin activity on expression of LacZ reporter
mRNAs containing the utrophin full-length 30UTR in
cultured C2C12 muscle cells. For these experiments, we
transfected a construct containing a transgene that
encodes a constitutively active variant of calcineurin
(pCnA
 ) together with the LacZ construct harboring the
utrophin full-length 30UTR (17). In agreement with the
ability of calcineurin to regulate the stability of utrophin A
transcripts, we observed that co-transfection of pCnA
 
with the reporter construct containing the utrophin full-
length 30UTR, led to an  2-fold (P<0.05) increase in
LacZ mRNA expression in comparison to empty vector
controls (pCIneo) (Figure 6C). Similarly, co-transfection
of pCnA
  with a deletion reporter construct containing
only the ﬁrst 596 nucleotides of the utrophin 30UTR also
led to an  2-fold (P<0.05) induction in reporter mRNA
levels in comparison to controls (Figure 6C). Notably, this
diﬀerence was eliminated upon further truncation of
the 30UTR to the ﬁrst 332 nucleotides (Figure 6C).
To demonstrate whether this regulation by calcineurin
also occurs in vivo, we injected primarily fast TA muscles
of mice with either the full-length 30UTR or the deleted
ARE version, along with pCnA
  or an empty vector
control (pCIneo). Muscles injected with the full-length
reporter along with pCnA
  showed an  1.4-fold enhance-
ment of LacZ mRNA expression compared with pCIneo
co-injected controls (P<0.05). In contrast, co-injection of
Figure 6. Calcineurin signaling regulates the stability of utrophin A mRNA through its 30UTR. In vitro stability assays were performed with soleus
(SOL) protein extracts from mice treated with vehicle or the calcineurin inhibitor FK506, and RNA isolated from 3-day old C2C12 myotubes.
(A) Example of ethidium bromide-stained agarose gels displaying utrophin A and S12 PCR products following 0, 30 and 60min incubation with
protein extracts. Note the greater amount of utrophin A mRNA remaining after 30 and 60min incubations with SOL extracts from vehicle-treated
mice as compared with SOL extracts from mice treated with FK506. (B) Quantitation of the relative half-life expressed as a percentage of values
obtained for utrophin A incubated with SOL extracts from vehicle treated mice. Note the signiﬁcant decrease in the half-life of utrophin A upon
incubation with SOL extracts from FK506-treated mice.
 Indicates a signiﬁcant diﬀerence from vehicle (P<0.05; n=3 independent experiments).
(C) C2C12 myoblasts were transfected with reporter constructs containing either the utrophin full-length 30UTR, or the ﬁrst 596 or 332 nucleotides
(Figure 2A), together with an empty vector (pCIneo) or a construct containing a constitutively active variant of calcineurin (pCnA
 ). Note that LacZ
reporter mRNA levels expressed from the utrophin full-length 30UTR and the ﬁrst 596 nucleotide constructs, are 50% higher in myotubes expressing
CnA
 . This diﬀerence is lost when LacZ mRNAs are fused to only the ﬁrst 332 nucleotides indicating the presence of a calcineurin-responsive
element between nucleotides 332 and 596.
 Indicates a signiﬁcant diﬀerence between pCIneo and pCnA
 transduced muscles (P<0.05; n=4
experiments done in triplicate). (D) Tibilais anterior muscles were injected with plasmids containing the utrophin full-length 30UTR or the utrophin
30UTR ARE reporter constructs along with the pCIneo or pCnA
 constructs. LacZ reporter mRNA levels from the full-length 30UTR construct are
signiﬁcantly increased when muscles ﬁbers have overexpressed pCnA
 , whereas no increase is observed in muscle ﬁbers injected with the 30UTR
ARE reporter construct.
 Indicates a signiﬁcant diﬀerence between pCIneo and pCnA
 transduced muscles (P<0.05; n=3–4 mice).
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levels from the 30UTR ARE reporter construct.
Therefore, nucleotides 332–596 in the utrophin 30UTR,
in addition to functioning as a speciﬁc region required to
maintain diﬀerences in mRNA expression between fast
and slow muscles, is also a calcineurin-responsive element.
Lastly, we wanted to determine the eﬀects of altered
calcineurin signaling on mRNA stability mediated by the
utrophin 30UTR. Therefore, we performed in vitro stabi-
lity assays with soleus muscle protein extracts obtained
from mice treated with either FK506 or vehicle, in the
presence of RNA isolated from C2C12 muscle cells
transfected with reporter constructs containing either the
utrophin full-length 30UTR or the 30UTR ARE reporter
constructs. The stability of utrophin full-length 30UTR
reporter mRNAs incubated with soleus muscle extracts of
FK506-treated mice decreased relative to vehicle controls
(Figure 7A). This observation is entirely consistent with
the eﬀect of calcineurin inhibitors on the stability of
utrophin A mRNA and with the ability of activated
calcineurin to promote reporter expression via the
utrophin 30UTR. Quantitative assessment over time of
reporter mRNAs fused to the utrophin full-length 30UTR
revealed that upon incubation with soleus protein extracts
from FK506-treated mice, the half-life of these transcripts
decreased by  25% (P<0.05) relative to vehicle-treated
controls (Figure 7B). In contrast, the half-life of reporter
mRNAs containing the utrophin 30UTR ARE incubated
in the presence of soleus protein extracts obtained from
FK506-treated mice was similar to those obtained for
reporter mRNAs fused to the utrophin full-length 30UTR
incubated with soleus extracts from vehicle-treated
mice (Figure 7B). These results show that inhibition of
calcineurin signaling promotes degradation of utrophin
mRNAs through the conserved ARE found within
the 30UTR.
DISCUSSION
We used a combination of approaches to gain insights into
the molecular events controlling expression of utrophin
A in fast and slow muscles. Here, we focused on the
contribution of post-transcriptional mechanisms. Using
an in vitro stability assay, we determined that utrophin A
mRNA degrades at a faster rate in the presence of fast
muscle proteins. In agreement with this, we also observed
that reporter mRNAs fused to the utrophin 30UTR
decayed at a faster rate upon incubation with fast
muscle extracts. Within the utrophin 30UTR, we uncov-
ered a conserved ARE with a prominent role in conferring
higher levels of utrophin A mRNA in slow muscles
relative to fast muscles. Finally, we demonstrated that
calcineurin aﬀects the stability of utrophin A mRNAs via
the conserved ARE. These results, together with our
previous observations (10,16,17), establish that both
transcriptional and post-transcriptional mechanisms act
in concert to promote increased expression of utrophin
A in slower, oxidative muscle ﬁbers. In fact, it appears
that the 3–4 fold enrichement in utrophin A mRNA and
protein levels seen in slow versus fast muscle can be
accounted for by equal contributions of transcriptional
and post-transcriptional events.
Stability of utrophinAmRNA in skeletal muscle
Post-transcriptional regulation of transcripts is becoming
increasingly recognized as an important regulatory event
in skeletal muscle maintenance and development [see (24)
for review]. Fast and slow skeletal muscles, in addition to
diﬀering in the proﬁles of mRNAs and proteins expressed,
also diﬀer in the patterns of activity they receive from
innervating motoneurons (45). Our previous work estab-
lished that utrophin is a relatively stable mRNA,
demonstrating a half-life of  20h that is unchanged
during myogenic diﬀerentiation of C2C12 muscle cells
in culture (46). Here, we show that stability of utrophin
A mRNAs in vivo is clearly diﬀerent between fast and
slow muscles, suggesting that the diﬀerent patterns of
activity can modulate the half-life of speciﬁc mRNAs in
muscle. Similar to utrophin A, expression of other
transcripts in muscle is also known to be regulated post-
transcriptionally via activity. For example, denervation of
muscle ﬁbers leads to an almost complete disappearance
Figure 7. Calcineurin signaling regulates utrophin 30UTR reporter
mRNA stability through the conserved ARE. In vitro stability assays
were performed with soleus (SOL) extracts obtained from mice treated
with vehicle or FK506, and RNA isolated from 3 day-old C2C12
myotubes transfected with reporter constructs containing the full-length
30UTR or the ARE-deleted version (30UTR ARE). (A) Example of
ethidium bromide-stained agarose gels displaying LacZ PCR products
following 0, 30 and 60min incubation with protein extracts. Note the
greater amount of LacZ mRNA fused to the utrophin full-length
30UTR that remain after 30 and 60min incubations with SOL extracts
from vehicle-treated mice versus incubation with extracts from FK506-
treated mice. Also, note the loss of this eﬀect upon deletion of the
conserved ARE. (B) Quantitation of the relative half-life expressed as a
percentage of values obtained for LacZ mRNA fused to the utrophin
full-length 30UTR incubated with SOL protein extracts from vehicle-
treated mice. Note the signiﬁcant decrease in the half-life of LacZ
mRNA with the full-length 3 UTR upon incubation with SOL extracts
from FK506-treated mice relative to SOL extracts from vehicle-treated
mice. Also, note the loss of this response to FK506 upon deletion of the
ARE.
 Indicates a signiﬁcant diﬀerence from utrophin full-length
30UTR (P<0.05; n=3 independent experiments).
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half-life of pre-synthesized mRNAs (25,47,48). Moreover,
it is becoming well established that post-transcriptional
mechanisms also have important roles in promoting
expression of the mitochondrial protein cytochrome c in
response to increased skeletal muscle activity particularly
in the early induction phase following electrical stimula-
tion (49,50). These observations, together with our current
ﬁndings, illustrate the importance of mRNA turnover in
regulating expression of speciﬁc transcripts in skeletal
muscle in response to altered levels of activity and among
muscle ﬁber types.
Implication of aconservedARE in theutrophin 3’UTR
It is now well recognized that ARE-mediated mRNA
turnover is an important regulatory process that controls
expression of distinct transcripts in all cell types [see for
review (38,51)]. A large percentage of mRNAs have now
been identiﬁed to contain AREs within their 30UTRs [up
to 5%, see (52)], emphasizing the importance of this
regulatory site in controlling the abundance of multiple
transcripts in cells placed under varying conditions. Close
inspection of the ARE contained within the utrophin
30UTR reveals the presence of two AUUUA motifs within
a conserved region of 16 nucleotides in length, overlapping
with a UUAUUUA (U/A) (U/A) nonamer. The presence
of the two AUUUA motifs and the nonamer suggest that
this particular ARE shares characteristics consistent with
motifs involved in mRNA degradation. Deletion of this
element resulted in an increase in the stability of the
reporter mRNA, thereby indicating that indeed, this
conﬁned region of the 30UTR acts as a destabilizing
element. Our additional studies further showed that this
element mediates its destabilizing eﬀects preferentially in
fast muscle.
Mechanisms regulating thestability ofutrophin AmRNA
It has been shown that ARE-containing transcripts are
rapidly deadenylated and degraded by one of two
processes in other cell systems. One involves the associa-
tion of the exosome, a large multiprotein enzymatic
complex, with ARE-containing transcripts (41,53). This
association of the exosome subsequently targets ARE-
containing mRNAs for degradation. The second pathway
involves a dynamic equilibrium, whereby ARE-containing
mRNAs are targeted to cellular entities [i.e. processing (P)
bodies or stress granules; (54,55)]. The 265 nucleotides
within the 332–596 region of the utrophin 30UTR which
contains the conserved ARE, has previously been shown
to have an important role in targeting utrophin mRNAs
to cytoskeletal-bound polysomes during myogenesis (30).
Since here we have shown that the same region in the
utrophin 30UTR can regulate the stability of mRNAs
in vivo, it appears likely that in the context of fast and slow
muscles, stability and targeting of utrophin A transcripts
are linked. Therefore, deciphering the intracellular sites
where utrophin A transcripts are enriched in fast and slow
muscle ﬁbers may provide important insights into the
mechanisms that regulate their turnover.
The ability of AREs to aﬀect the turnover rates of host
mRNAs involves recruitment of ARE-binding proteins
(ARE-bp) [see for review (38,56)]. The binding of
these proteins to AREs can lead to either stabilization
or accelerated degradation of mRNAs. ARE-bp such
as AUF1 family members and KRSP are examples of
trans-acting factors that promote degradation of ARE-
containing mRNAs (57,58). Conversely, the Hu family of
proteins, namely HuR, B, C and D, are the most well
characterized ARE-bps known to promote stabilization of
mRNAs (59). In skeletal muscle cells in culture, HuR has
been shown to associate with the AREs found in the
30UTR of transcripts encoding MyoD, myogenin, p21 and
AChE (27,29,60). In this context, the levels of HuR as well
as its subcellular localization have been shown to play
important roles in stabilizing these various mRNAs
during myogenesis. Conversely, activation of p38
MAPK signaling promotes stabilization of MyoD, myo-
genin and p21 mRNAs by preventing interactions between
the destabilizing protein KRSP with ARE (28).
Previous work has shown that chronic stimulation of
skeletal muscle leads to increased expression of cyto-
chrome c accompanied by the loss of binding of a
potentially destabilizing  37kDa protein to the cyto-
chrome c 30UTR (49). Considering that chronic stimula-
tion promotes conversion of skeletal muscles to a slower
oxidative phenotype (45), these latter observations are
consistent with the notion that fast muscle protein extracts
contain one or more factors that promote destabilization
of normally low abundance target mRNAs. Previously,
using UV crosslinking assays, we showed greater binding
to the utrophin 30UTR of a 37kDa protein from fast
muscle relative to slow muscle protein extracts (16).
Collectively, these observations thus suggest that conver-
sion and/or promotion of the slow myoﬁber program
leads to a loss in the association of destabilizing factor(s)
to ARE sites found in the 30UTR of mRNAs that reﬂect
this particular phenotype including cytochrome c and
utrophin A transcripts.
Roleof calcineurin inmRNA stabilization
It is now well established that calcineurin takes part in
maintaining and promoting expression of the slower, high
oxidative, myoﬁber phenotype by regulating at the
transcriptional level, expression of slower myoﬁber genes
(22,61). In this widely accepted model, diﬀerent patterns
of electrical activity controlled by innervating motor
neurons lead to distinct intracellular waves of Ca
+2
which activate calcineurin. In turn, activated calcineurin
dephosphorylates NFAT and MEF2 that become free to
stimulate transcription of a subset of genes via direct
interactions with DNA regulatory motifs found within
their promoter regions. However, recent detailed exam-
ination of calcineurin-null mice has led to the suggestion
that this phosphatase regulates expression of the slower
myoﬁber phenotype through additional factors other than
NFAT and MEF2 (62).
In skeletal muscle, changes in intracellular calcium have
been linked previously to alterations in the turnover of
mRNAs encoding AChE and the inwardly rectifying
Nucleic Acids Research,2008, Vol. 36,No. 3 835potassium channel 1 (63,64). In this context, alterations of
calcineurin activity in skeletal muscle cells grown in
culture have been shown to inﬂuence the stabilization/
degradation of AChE transcripts during myogenic diﬀer-
entiation (65). Interestingly, calcineurin has also been
shown previously to regulate speciﬁcally ARE-mediated
mRNA turnover. In particular, calcineurin inhibition
leads to the destabilization of IL-3 mRNAs and, notably,
this eﬀect is lost upon deletion of the ARE from the
IL-3 30UTR (66). In addition, inhibition of calcineurin
activity has been shown to alter parathyroid mRNA levels
while also promoting interactions between AUF1 and
the parathyroid 30UTR (67). In the present study, we
demonstrate that calcineurin activity can inﬂuence the
turnover of utrophin A mRNA through an ARE-
dependent mechanism. Therefore, these results suggest
that post-transcriptional events operating at the level of
ARE-mediated mRNA decay provide additional mechan-
isms whereby calcineurin can promote expression of genes
that characterize the slower oxidative myoﬁber program.
Together with its known transcriptional eﬀects on
expression of slower, high-oxidative genes in muscle, it
appears highly eﬃcient and optimal for calcineurin
signaling to concomitantly participate in the post-tran-
scriptional mechanisms regulating the turnover of these
target mRNAs in muscle ﬁbers in vivo.
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